PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound

British Journal of Cancer

Volumn 97, Issue 6, 2007, Pages 785-791

  Cen, L ^a   Hsieh, F C ^a   Lin, H J ^a,b   Chen, C S ^a,b   Qualman, S J ^a,b   Lin, J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

AKT; PDK 1; Rhabdomyosarcoma; Small molecular inhibitor; Tissue microarray

Indexed keywords

ENZYME INHIBITOR; OSU 03012; PHOSPHOINOSITIDE DEPENDENT KINASE 1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL VIABILITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; TISSUE MICROARRAY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMONES; ENZYME INHIBITORS; FEMALE; HUMANS; INFANT; MALE; MORPHOLINES; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 34548598298     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603952     Document Type: Article

References (23)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, Cohen P (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B[alpha]. Curr Biol 7: 261-269
2. Alessi DR, Kozlowski MT, Weng Q-P, Morrice N, Avruch J (1998) 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 8: 69-81
3. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857
4. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR (2000) Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 484: 217-223
5. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271
6. Clark A, West K, Streicher S, Dennis P (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717
7. deGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510-1516
8. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and Phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9: 594-600
9. Flynn P, Wong M, Zavar M, Dean NM, Stokoe D (2000) Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol 10: 1439-1442
10. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ (1998) Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281: 2042-2045
11. Lin H, Hsieh F, Song H, Lin J (2005) Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 93: 1372-1381
12. Mora A, Komander D, van Aalten DMF, Alessi DR (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 15: 161-170
13. Nesterov A, Lu X, Johnson M, Miller G, Ivanshchenko Y, Kraft A (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774
14. Page C, Lin H, Jin Y, Castle V, Nunez G, Huang M, Lin J (2000) Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20: 407-416
15. Qualman SJ, Coffin CM, Newton WA, Hojo H, Triche TJ, Parham DM, Crist WM (1998) Intergroup rhabdomyosarcoma study: update for pathologists. Pediatr Dev Pathol 1: 550-561
16. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (1999) Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649
17. Stokoe D, Stephens L, Copeland T, Gaffney P, Reese C, Painter G, Holmes A, McCormick F, Hawkins P (1997) Dual role of phosphatidylinositol-3,4,5- trisphosphate in the activation of protein kinase B. Science 567-570
18. Sun M, Wang G, Paciga JE, Feldman RI, Yuan Z-Q,Ma X-L, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ (2001) AKT1/PKB{alpha} kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431-437
19. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer R (2006) 3-phosphoinositide- dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 6: 77
20. Xie Z, Zeng X, Waldman T, Glazer R (2003) Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 63: 5370-5375
21. Zeng X, Xu H, Glazer R (2002) Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase C alpha. Cancer Res 62: 3538-3543
22. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan K-H, Yang Y, Yang W, Smith TL, Shi D, Yu D (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788
23. Zhu J, Huang J-W, Tseng P-H, Yang Y-T, Fowble J, Shiau C-W, Shaw Y-J, Kulp SK, Chen C-S (2004) From the cyclooxygenase-2 Inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64: 4309-4318